Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PA-111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
PA-111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
PA-111: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
JC005 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
JC005 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
JC005: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Radanstobart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Radanstobart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Radanstobart: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
PF-07940369 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
PF-07940369 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
PF-07940369: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Etomoxir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Etomoxir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Etomoxir: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
QLS1209 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
QLS1209 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
QLS1209: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
PhOx-430 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
PhOx-430 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
PhOx-430: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Bevemipretide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Bevemipretide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Bevemipretide: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
VIB-9600 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
VIB-9600 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
VIB-9600: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
AKB-7414 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
AKB-7414 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AKB-7414: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
68Ga-R10602 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
68Ga-R10602 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
68Ga-R10602: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
NLS-FMAU Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
NLS-FMAU Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
NLS-FMAU: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →